ASX June Health Winners: Sector falls 1.05pc but Amplia up 300pc after positive trial news
Morgans healthcare analyst Iain Wilkie said June likely saw some tax loss selling before EOFY
Amplia up 300% in June after complete responses in two advanced (metastatic) pancreatic cancer patients in ACCENT trial
While the broader market showed resilience to global geopolitical and economic pressures in June, the ASX 200 Health Care index remained in poor shape, falling 1.05% for the month.
The sector remains the worst-performing ASX sector year-to-date and the only one in the red, down 6.64%.
Morgans healthcare analyst Iain Wilkie told Stockhead the first half of 2025 had been highly volatile for the global healthcare sector, driven by policy uncertainty in the US.
He said Donald Trump's policies were impacting the sector including funding cuts and shakeups to regulatory agencies such as the US Food and Drug Administration (FDA).
In addition, Trump is advancing the 'Most Favored Nation' (MFN) drug pricing policy, which seeks to align US prescription medicine prices with the lowest levels paid in other developed nations.
While the policy's full implementation remains pending, it has already created uncertainty for pharmaceutical companies, with no clear path yet on how it will be enforced or the potential market ramifications.
Wilkie said the sector likely also saw some tax loss selling in June – the final month of the Australian financial year – with many investors crystallising losses in this space to offset gains made in other parts of their portfolios.
"We often view this month as a potential opportunity to stock up on some companies at a discount if we continue to see long term value in them and approaching significant catalysts," he said.
How ASX biotechs performed in June
CODE COMPANY PRICE 1 MONTH RETURN % MARKET CAP
ATX Amplia Therapeutics 20 300.0% 91.17
NSB Neuroscientific 8.7 50.0% 36.58
OSL Oncosil Medical 120 50.0% 17.06
EZZ EZZ Life Science 234 49.5% 116.05
NYR Nyrada Inc. 24 45.5% 50.62
CGS Cogstate Ltd 174.5 33.7% 295.62
ALA Arovella Therapeutic 10 31.6% 112.91
AHX Apiam Animal Health 52 28.4% 92.89
PEB Pacific Edge 9.6 28.0% 81.19
IRX Inhalerx Limited 3.8 26.7% 7.90
NC6 Nanollose Limited 6.7 26.4% 20.74
VLS Vita Life Sciences 225 23.6% 123.28
SHG Singular Health 37 21.3% 120.68
CSX Cleanspace Holdings 52 20.9% 39.89
IPD Impedimed Limited 3.5 16.7% 79.07
ALC Alcidion Group Ltd 10 16.3% 147.72
IVX Invion Ltd 11 15.8% 8.49
CU6 Clarity Pharma 250 15.7% 763.53
NUZ Neurizon Therapeutic 15.5 14.8% 76.31
ARX Aroa Biosurgery 58 13.7% 193.22
SOM SomnoMed Limited 65 11.1% 138.31
COH Cochlear Limited 30042 10.7% 19,917.31
CTQ Careteq Limited 1.1 10.0% 2.61
ACW Actinogen Medical 2.3 9.5% 73.07
EBR EBR Systems 119.5 7.7% 523.20
DVL Dorsavi Ltd 1.5 7.1% 12.62
PYC PYC Therapeutics 129.5 7.0% 755.32
COV Cleo Diagnostics 39 6.8% 31.82
OCA Oceania Healthc Ltd 63 6.8% 456.27
CMB Cambium Bio Limited 21 5.0% 3.84
IDX Integral Diagnostics 254 5.0% 904.56
RMD ResMed Inc. 3935 3.8% 23,160.79
EMD Emyria Limited 2.8 3.7% 16.51
EBO Ebos Group Ltd 3559 3.5% 1,919.95
TRP Tissue Repair 19 2.7% 11.19
EMV Emvision Medical 174 2.4% 149.23
SNZ Summerset Grp Hldgs 1044 2.3% 2,414.13
NEU Neuren Pharmaceut. 1411 1.7% 1,811.96
SPL Starpharma Holdings 8.8 1.1% 36.39
PME Pro Medicus Limited 28508 1.1% 15,301.07
MYX Mayne Pharma Ltd 500 1.0% 381.86
SHL Sonic Healthcare 2679 0.4% 12,836.39
1AD Adalta Limited 0.2 0.0% 2.14
AGH Althea Group 2.5 0.0% 20.56
ANR Anatara Ls Ltd 0.5 0.0% 1.07
CHM Chimeric Therapeutic 0.4 0.0% 9.07
DOC Doctor Care Anywhere 10.5 0.0% 42.16
DXB Dimerix Ltd 57.5 0.0% 346.85
EOF Ecofibre Limited 2 0.0% 7.58
EPN Epsilon Healthcare 2.4 0.0% 8.29
ICR Intelicare Holdings 0.7 0.0% 2.92
MEM Memphasys Ltd 0.5 0.0% 8.93
TD1 Tali Digital Limited 0.1 0.0% 4.10
CTE Cryosite Limited 74.5 -0.7% 36.36
FPH Fisher & Paykel H. 3363 -0.9% 6,557.10
SDI SDI Limited 83 -2.4% 97.47
ACL Au Clinical Labs 278 -2.5% 388.89
MSB Mesoblast Limited 165.5 -2.6% 1,810.36
NXS Next Science Limited 6.7 -2.9% 32.14
CSL CSL Limited 23948 -3.0% 115,358.67
AHC Austco Healthcare 29 -3.3% 107.40
CBL Control Bionics 2.9 -3.3% 9.43
LDX Lumos Diagnostics 2.7 -3.6% 19.46
CUV Clinuvel Pharmaceut. 1038 -3.7% 451.46
REG Regis Healthcare Ltd 784 -3.8% 1,167.64
ANN Ansell Limited 3029 -4.0% 4,490.73
SIG Sigma Health Ltd 299 -4.2% 17,142.40
RHC Ramsay Health Care 3669 -4.2% 7,017.07
IXC Invex Ther 8.9 -4.3% 6.69
PTX Prescient Ltd 4.4 -4.3% 33.02
PAR Paradigm Bio. 30.5 -4.7% 146.04
OCC Orthocell Limited 117.5 -5.2% 305.40
AYA Artryalimited 72 -5.3% 79.35
AVR Anteris Technologies 614 -5.5% 92.84
ONE Oneview Healthcare 25 -5.7% 190.96
FRE Firebrickpharma 6.2 -6.1% 14.37
AGN Argenica 76 -6.2% 95.43
TYP Tryptamine Ltd 3 -6.3% 43.06
TLX Telix Pharmaceutical 2442 -6.4% 7,003.27
AFP Aft Pharmaceuticals 243 -6.5% 254.83
CDX Cardiex Limited 4 -7.0% 22.00
PGC Paragon Care Limited 36.5 -7.6% 620.74
AVH Avita Medical 171.5 -7.8% 113.37
MVF Monash IVF Group Ltd 70.5 -7.8% 280.54
RAC Race Oncology Ltd 117.5 -8.2% 203.28
1AI Algorae Pharma 0.55 -8.3% 8.44
RAD Radiopharm 2.2 -8.3% 53.21
PNV Polynovo Limited 119.5 -8.8% 829.01
NAN Nanosonics Limited 405 -8.8% 1,155.80
VIT Vitura Health Ltd 6.2 -8.8% 41.72
IMC Immuron Limited 6.1 -9.0% 15.21
ATH Alterity Therap Ltd 1 -9.1% 91.27
PER Percheron 1 -9.1% 10.33
VHL Vitasora Health Ltd 3.9 -9.3% 61.50
TRJ Trajan Group Holding 71.5 -9.5% 111.24
ECS ECS Botanics Holding 0.9 -10.0% 11.66
LGP Little Green Pharma 9.9 -10.0% 33.44
HLS Healius 78.5 -10.3% 544.60
M7T Mach7 Tech Limited 33 -10.8% 82.02
MDR Medadvisor Limited 8.1 -11.0% 53.11
CVB Curvebeam Ai Limited 7.1 -11.3% 23.76
RHT Resonance Health 3.9 -11.4% 18.84
IBX Imagion Biosys Ltd 1.1 -12.0% 2.42
IME Imexhs Limited 29 -12.1% 15.56
BMT Beamtree Holdings 25 -12.3% 69.64
MX1 Micro-X Limited 4.9 -12.5% 32.69
IMR Imricor Med Sys 152 -12.6% 496.69
ZLD Zelira Therapeutics 44 -12.9% 5.23
IMU Imugene Limited 44.2 -13.3% 104.54
LTP Ltr Pharma Limited 29 -13.4% 36.39
BOT Botanix Pharma Ltd 32 -13.5% 605.72
CMP Compumedics Limited 25.5 -13.6% 49.02
GLH Global Health Ltd 6.8 -13.9% 3.92
PSQ Pacific Smiles Grp 154.5 -14.4% 239.20
RGT Argent Biopharma Ltd 8.1 -14.7% 5.77
AT1 Atomo Diagnostics 1.4 -15.2% 10.32
IDT IDT Australia Ltd 8.9 -15.2% 40.82
EYE Nova EYE Medical Ltd 11 -15.4% 32.68
CC5 Clever Culture 1.6 -15.8% 30.03
UCM Uscom Limited 1.6 -15.8% 4.01
IMM Immutep Ltd 24 -15.8% 350.49
IIQ Inoviq Ltd 37 -15.9% 41.30
BDX Bcaldiagnostics 6.3 -16.0% 24.52
MVP Medical Developments 54.5 -16.2% 61.40
CYP Cynata Therapeutics 15 -16.7% 38.41
PCK Painchek Ltd 4.5 -16.7% 73.68
RHY Rhythm Biosciences 5.4 -16.9% 15.34
UBI Universal Biosensors 3.5 -18.6% 10.43
RCE Recce Pharmaceutical 29 -19.4% 82.19
BIT Biotron Limited 0.2 -20.0% 2.65
BP8 Bph Global Ltd 0.2 -20.0% 2.10
SNT Syntara Limited 5.3 -20.9% 82.87
OIL Optiscan Imaging 11 -21.4% 100.24
PIQ Proteomics Int Lab 32.5 -23.5% 59.69
GSS Genetic Signatures 36.5 -24.0% 86.31
CYC Cyclopharm Limited 91 -24.2% 102.25
VFX Visionflex Group Ltd 0.15 -25.0% 6.74
NOX Noxopharm Limited 5.4 -26.0% 15.20
HIQ Hitiq Limited 1.4 -26.3% 6.90
CAN Cann Group Ltd 1 -28.6% 7.00
NTI Neurotech Intl 1.5 -28.6% 18.89
4DX 4Dmedical Limited 24 -29.4% 114.05
AVE Avecho Biotech Ltd 0.35 -30.0% 12.69
ACR Acrux Limited 1.6 -30.4% 7.34
ADR Adherium Ltd 0.4 -33.3% 4.49
PAB Patrys Limited 0.1 -33.3% 2.37
VBS Vectus Biosystems 4 -33.3% 2.02
ILA Island Pharma 14 -37.8% 30.69
TRI Trivarx Ltd 0.8 -38.5% 4.96
OSX Osteopore Limited 1.1 -38.9% 2.20
TRU Truscreen 1.6 -40.7% 11.75
MAP Microbalifesciences 8.5 -45.2% 43.78
HMD Heramed Limited 0.7 -46.2% 9.63
Amplia Therapeutics (ASX:ATX) rose 300% in June after a series of positive announcements including confirmed pathological complete responses recorded in two advanced (metastatic) pancreatic cancer patient as part of its ACCENT trial.
The trial is investigating Amplia's best-in-class FAK inhibitor narmafotinib in combination with standard-of-care chemotherapies gemcitabine and Abraxane in patients with metastatic pancreatic cancer.
Amplia also announced in June it had received US ethics approval of the protocol for its forthcoming Phase II clinical trial of narmafotinib in combination with the chemotherapy FOLFIRINOX in advanced pancreatic cancer.
NeuroScientific Biopharmaceuticals (ASX:NSB) was up 50% in June after announcing it had acquired 100% of Perth-based unlisted company Isopogen WA, which owns or holds the rights to commercialise the patented StemSmart stem cell technology.
Furthermore, Neuroscientific said previous clinical data showed StemSmart was effective in preventing graft-versus-host disease (GvHD), a common complication of bone-marrow transplants.
A phase I clinical trial in adults with steroid-refractory GVHD, and a series of children treated on compassionate grounds for steroid-refractory GVHD found the majority of adults and children responded to StemSmartTM with a complete or partial resolution of symptoms and improved survival.
Clinical-stage radiopharmaceutical company Clarity Pharmaceuticals (ASX:CU6) rose 15.7% in June after a series of positive announcements including positive topline data from two trials.
Its diagnostic phase II trial DISCO confirmed that Cu-SARTATE was safe and highly effective compared to standard-of-care imaging at detecting lesions in patients with neuroendocrine tumours.
Topline results from Clarity's Phase II SABRE trial showed that Cu-SAR-Bombesin was safe, well tolerated, and effective at detecting prostate cancer in patients with biochemical recurrence who had negative or unclear results on standard scans, including PSMA PET.
Neurizon Therapeutics (ASX:NUZ) rose 14.8% with a series of positive announcements including positive trial results for its lead drug candidate NUZ-001.
Preclinical data demonstrated significant neuroprotective effects of NUZ-001 and its active metabolite NUZ-001 Sulfone, in a zebrafish model of Huntington's disease.
Neurizon also reported encouraging new rodent preclinical pharmacokinetic (PK) data for NUZ-001 and NUZ-001 Sulfone, showing it effectively crosses the blood-brain barrier.
The ability of therapeutics to access the central nervous system remains a major barrier in treatment of neurodegenerative diseases such as amyotrophic lateral sclerosis, the most common form of motor neurone disease, for which the company is focused.
At Stockhead, we tell it like it is. While Neurizon Therapeutics is a Stockhead advertiser, the company did not sponsor this article.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
AU Financial Review
37 minutes ago
- AU Financial Review
Tech workers, scientists take $600k pay cuts to flee Trump's America
It might be the Peter Allen effect, or it could be Donald Trump, but Australians working in the US are calling Australia home again as they leave lucrative jobs in tech and science for opportunities Down Under. But those returning find they are competing for jobs with Americans fleeing the US.
ABC News
an hour ago
- ABC News
EV buses join Perth's wider suburban network, 'milestone' for diesel phase-out
The first fleet of electric buses has entered Perth's wider suburban network, with the WA Transport Minister Rita Saffioti labelling it an important milestone in the government's push to phase out diesel. Eleven of the electric vehicles are ready to operate out of Transperth's Malaga depot, which is undergoing a $12 million upgrade to allow for the new infrastructure. Sixteen chargers have already been installed at the depot and a further 90 are expected to be added by the end of September. According to the government, the upgrade will see the depot become the state's largest EV bus charging complex, and has already included the installation of solar panels and batteries to power the facility. "A few weeks ago we announced the last diesel bus to come out of the Malaga depot in relation to its manufacture, so the last diesel bus produced in WA has already occurred." The minister said it was hoped the final diesel bus would exit the network by 2043. The electric buses use imported parts from Sweden, before being locally assembled at another facility in Malaga. Ninety of them set to be deployed across Perth over the next eight months. Each electric bus can travel up to 300 kilometres on a single charge, which the government said saved about 40 tonnes of carbon dioxide emissions a year. High frequency bus routes, like the 960 and 950, will be among the first to be serviced by the fleet at the Malaga depot, alongside routes passing through the Morley Galleria shopping centre and Ballajura and Morley train stations. An initial rollout of the vehicles began in Perth's CBD last September, with 18 added to the CAT Bus routes, which also saw Elizabeth Quay Bus Depot fitted out with new charging infrastructure. Ms Saffioti said EV upgrades to other depots were already underway, or planned for, at the Karrinyup and Claisebrook bus depots, with a new EV bus depot set for Bayswater. "Not only are electric buses cleaner and better for the environment, they're also cheaper to operate in the long term, which means better value for money for WA taxpayers," Ms Saffioti said. "It's 22,000 litres of diesel per bus per year, so massive savings." The Liberals said they would be watching the rollout of the new buses closely. "We are obviously looking to see how that rollout goes, noting there have been some concerning issues with the C-series trains that have been manufactured on this government's watch," shadow cabinet minister Liam Staltari said. Mr Staltari was referring to a recent union survey of train drivers that highlighted concerns over the comfort and braking ability of the C-series trains. In response, the Public Transport Authority said there were no braking issues on the trains, stating the C-Series had excellent acceleration and braking features. In parliament, Ms Saffioti defended the C-series and said there was always going to be an adjustment period for the drivers.
News.com.au
2 hours ago
- News.com.au
Revealed: The Melbourne Cup is set for a major prizemoney boost for the new racing season
Australia's most famous race, the Group 1 Melbourne Cup (3200m), has got richer. This masthead has established a long-held Victoria Racing Club (VRC) dream – a $10m Melbourne Cup – has finally been realised. Racing Victoria is set to confirm prizemoney for the 2025-26 season, as early as this week. The Melbourne Cup has carried an $8m prizemoney pool since 2020 – marketed as $8.75m including the iconic 18-carat gold three-handled trophy, valued at $750,000. It is only the sixth significant prizemoney boost for 'the race that stops a nation' since 1990 – the first seven-figure ($1m) purse. The Melbourne Cup has increased in 2000 ($2m), 2009 ($5.5m), 2010-17 ($6-6.2m), 2018 ($7.3m) and 2019 ($8m). RV controls prizemoney in the thoroughbred racing industry. The VRC has lobbied RV since 2022 for a $10m Melbourne Cup, as part of annual industry-wide prizemoney submissions to RV. This masthead in May revealed the latest VRC bid again included a $10m Cup wish. RV rejected past submissions due to a tough economic and wagering environment. Wagering returns, which fund the racing industry, dropped 10-15 per cent year-on-year after an explosion during the Covid pandemic. While wagering income and cost control remains crucial, better collaboration between RV and stakeholders, including racing clubs has allowed for important prizemoney adjustments. The total Victorian prizemoney pool – $316m last season – is likely to largely be retained but greater flexibility at club level, in particular, to redistribute funds has afforded select changes. It is understood the VRC has been able to trim prizemoney off other feature races to achieve the $1m and change required to secure a $10m Melbourne Cup. The All-Star Mile and Australian Cup dropped from $3m to $2.5m last season. The Group 1 features could be subject to further reductions. RV chief executive Aaron Morrison declined to comment on prizemoney discussions. However, Morrison said any changes for the upcoming season would benefit Victorian racing from grassroots to the top tier. Australia's best race, the Group 1 W.S Cox Plate (2040m), could jump to $6m – up from $5m – ahead of a historic last weight-for-age championship on the traditional Moonee Valley racecourse. The Valley is being redeveloped after the 2025 Cox Plate, with a return to racing on a reconfigured circuit slated for 2027. RV has yet to anoint a host for the 2026 Cox Plate but Flemington remains the logical frontrunner. The $5m Caulfield Cup (2400m) is likely to remain unchanged prizemoney wise however the purses of other Melbourne Racing Club events could be adjusted to afford select increases.
